ENZY — Enzymatica AB (publ) Share Price
0.000.00%
Last trade - 00:00- SEK832.58m
- SEK759.57m
- SEK45.58m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.72 | ||
| Price to Tang. Book | 7.56 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 18.27 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.66% | ||
| Return on Equity | -42.04% | ||
| Operating Margin | -114.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 111.25 | 57.24 | 48.95 | 50.9 | 45.58 | 78 | 109 | -5.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.
Directors
- Bengt Baron NEC (58)
- Claus Egstrand CEO (60)
- Therese Filmersson DCE (52)
- Stefan Olsson OTH (51)
- Kristoffer Ahlerup OTH (44)
- Charlotte Andersson OTH (49)
- Ulf Blom OTH (52)
- Johan Lindvall OTH (47)
- Ann Christine Provoost OTH (54)
- Malin Richter OTH (53)
- Mats Andersson DRC (62)
- Fredrik Lindberg DRC (62)
- Marianne Dicander Alexandersson IND (62)
- Louise Nicolin IND (47)
- Gudmundur Palmason IND (49)
- Helene Willberg IND (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 10th, 2007
- Public Since
- June 14th, 2011
- No. of Employees
- 21
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 242,735,108
- Address
- Ideon Science Park, Scheelevagen 19, LUND, 223 70
- Web
- https://www.enzymatica.se/
- Phone
- +46 462863100
- Contact
- Claus Egstrand
- Auditors
- Deloitte AB
Upcoming Events for ENZY
Enzymatica AB (publ) Annual Shareholders Meeting
Q2 2025 Enzymatica AB (publ) Earnings Release
Similar to ENZY
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cinclus Pharma Holding publ AB
OMX Nordic Exchange Stockholm
Corline Biomedical AB
OMX Nordic Exchange Stockholm
FAQ
What is the Enzymatica AB (publ) share price?
As of Today at 20:29 UTC, shares in Enzymatica AB (publ) are trading at SEK3.43. This share price information is delayed by 15 minutes.
How has the Enzymatica AB (publ) share price performed this year?
Shares in Enzymatica AB (publ) last closed at SEK3.43 and the price had moved by +6.9% over the past 365 days. In terms of relative price strength the Enzymatica AB (publ) share price has outperformed the FTSE Global All Cap Index by +5.02% over the past year.
What are the analyst and broker recommendations for Enzymatica AB (publ)?
There is no consensus recommendation for this security.
Find out moreWhat is the Enzymatica AB (publ) dividend yield?
Enzymatica AB (publ) does not currently pay a dividend.
Does Enzymatica AB (publ) pay a dividend?
Enzymatica AB (publ) does not currently pay a dividend.
When does Enzymatica AB (publ) next pay dividends?
Enzymatica AB (publ) does not currently pay a dividend.
How do I buy Enzymatica AB (publ) shares?
To buy shares in Enzymatica AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Enzymatica AB (publ)?
As of the previous close price of SEK3.43, shares in Enzymatica AB (publ) had a market capitalisation of SEK832.58m.
Where are Enzymatica AB (publ) shares listed?
Here are the trading details for Enzymatica AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ENZY
What kind of share is Enzymatica AB (publ)?
Based on an overall assessment of its quality, value and momentum Enzymatica AB (publ) is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Enzymatica AB (publ) share price forecast for 2025?
The analyst consensus target price for shares in Enzymatica AB (publ) is SEK3.88. That is 13.12% above the last closing price of SEK3.43.
Analysts covering Enzymatica AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.30 for the next financial year.
Find out moreWhat is the trend in the Enzymatica AB (publ) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Enzymatica AB (publ). Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +94.39%.
As of the last closing price of SEK3.43, shares in Enzymatica AB (publ) were trading +57.09% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Enzymatica AB (publ) PE Ratio?
The Enzymatica AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK3.43.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Enzymatica AB (publ)?
Enzymatica AB (publ)'s management team is headed by:
- Bengt Baron - NEC
- Claus Egstrand - CEO
- Therese Filmersson - DCE
- Stefan Olsson - OTH
- Kristoffer Ahlerup - OTH
- Charlotte Andersson - OTH
- Ulf Blom - OTH
- Johan Lindvall - OTH
- Ann Christine Provoost - OTH
- Malin Richter - OTH
- Mats Andersson - DRC
- Fredrik Lindberg - DRC
- Marianne Dicander Alexandersson - IND
- Louise Nicolin - IND
- Gudmundur Palmason - IND
- Helene Willberg - IND